A Landmark Vitamin K2 Study
Results of a three-year trial on bone health in 244 postmenopausal women.
Results are in for a long-awaited clinical trial on vitamin K2 and postmenopausal bone health. In the three-year study, 244 women supplemented daily with MenaQ7 vitamin K2 or placebo, and researchers measured their bone health improvements each year.
Compared to placebo, women who consumed vitamin K2 at 180 mcg daily experienced significantly less bone loss. Most striking is that MenaQ7 users saw an average 51% decrease in undercarboxylated (inactive) osteocalcin, the protein that helps move calcium from the blood to the bones. Placebo users saw inactive osteocalcin levels decrease by just 4%. The activation of osteocalcin remains the primary selling point for vitamin K2 in the bone health market, since vitamin D and calcium interact with bone health through other factors.
NattoPharma (Høvik, Norway), the industry supplier of MenaQ7, adds that bone mineral content and bone mineral density (BMD) also statistically improved.
The total compliance rating in the study was 91.4%.
